Gangxiong Huang
Overview
Explore the profile of Gangxiong Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Feng R, He B, Wang J, Xian N, Huang G, et al.
Front Mol Biosci
. 2021 Dec;
8:777370.
PMID: 34950702
Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal carcinoma (EC) in China. Although the PD-1 inhibitor pembrolizumab has been approved to treat patients with EC, its...
2.
Hu L, Chen L, Xiao Z, Zheng X, Chen Y, Xian N, et al.
JCI Insight
. 2021 Dec;
7(2).
PMID: 34905507
Programmed death-1 homolog (PD-1H) is a coinhibitory molecule that negatively regulates T cell-mediated immune responses. In this study, we determined whether ablation of T cell-associated PD-1H could enhance adoptive T...
3.
Huang B, Luo L, Wang J, He B, Feng R, Xian N, et al.
Oncoimmunology
. 2020 Feb;
9(1):1684127.
PMID: 32002297
The application of chimeric antigen receptor (CAR)-T cell therapy in patients with advanced solid tumors remains a significant challenge. Simultaneously targeting antigen and the solid tumor microenvironment are two major...
4.
Katreddy R, Bollu L, Su F, Xian N, Srivastava S, Thomas R, et al.
Oncogenesis
. 2018 Jan;
7(1):5.
PMID: 29358623
The oncogenic epidermal growth factor receptor (EGFR) is commonly overexpressed in solid cancers. The tyrosine kinase activity of EGFR has been a major therapeutic target for cancer; however, the efficacy...
5.
Yang Y, Huang G, Zhou Z, Fewell J, Kleinerman E
Mol Cancer Ther
. 2017 Oct;
17(1):130-139.
PMID: 29079708
The metastatic potential of osteosarcoma cells is inversely correlated to cell surface FAS expression. Downregulation of FAS allows osteosarcoma cells to escape FAS ligand-mediated apoptosis when they enter a FAS...
6.
Kiany S, Huang G, Kleinerman E
Oncoimmunology
. 2017 Sep;
6(8):e1333214.
PMID: 28919994
There is a crucial need for a new therapeutic approach for osteosarcoma (OS) lung metastasis since this disease remains the main cause of mortality in OS. We previously demonstrated that...
7.
Huang G, Nishimoto K, Yang Y, Kleinerman E
Adv Exp Med Biol
. 2014 Jun;
804:203-17.
PMID: 24924176
The lungs are the most common site for the metastatic spread of osteosarcoma. Success in using chemotherapy to improve overall survival has reached a plateau. Understanding the biologic properties that...
8.
Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman E
Cancer Res
. 2011 Dec;
72(4):908-16.
PMID: 22186140
The ability of osteosarcoma cells to form lung metastases has been inversely correlated to cell surface Fas expression. Downregulation of Fas allows osteosarcoma cells to circumvent FasL-mediated apoptosis upon entrance...
9.
Huang G, Yu L, Cooper L, Hollomon M, Huls H, Kleinerman E
Cancer Res
. 2011 Nov;
72(1):271-81.
PMID: 22075555
The treatment of osteosarcoma pulmonary metastases remains a challenge. T cells genetically modified to express a chimeric antigen receptor (CAR), which recognizes a tumor-associated antigen, have shown activity against hematopoietic...
10.
Huang G, Zhou Z, Wang H, Kleinerman E
Cancer
. 2011 Oct;
118(8):2106-16.
PMID: 22009261
Background: TC-71 Ewing sarcoma cells overexpress vascular endothelial growth factor (VEGF) with a shift from the 189 to the 165 isoform. Methods: The effect of CAPER-α on the expression of...